



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61K 47/36, 9/22	(11) International Publication Number: WO 98/00170 (43) International Publication Date: 8 January 1998 (08.01.98)
(21) International Application Number: PCT/NL97/00374 (22) International Filing Date: 1 July 1997 (01.07.97) (30) Priority Data: 962018214 1 July 1996 (01.07.96) EP (34) Countries for which the regional or international application was filed: GB et al. 60/031,671 22 November 1996 (22.11.96) US (71) Applicant (for all designated States except US): UNIVER- SITEIT UTRECHT [NL/NL]; Sorbonnelaan 16, NL-3584 CA Utrecht (NL). (72) Inventor; and (75) Inventors/Applicants (for US only): HENNINK, Wilhelmus; Everhardus [NL/NL]; Zuidplaspolder 120, NL-2743 CZ Waddinxveen (NL). VAN DIJK-WOLTHUIS, Wendel- moed, Nelletha, Eleonora [NL/NL]; Van Swietenstraat 9, NL-2334 EA Leiden (NL). (74) Agent: SMULDERS, Th. A. H. J., Verenigde Octrooi- reurs, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KR, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: HYDROLYSABLE HYDROGELS FOR CONTROLLED RELEASE. (57) Abstract <p>The present invention relates to a biodegradable hydrogel comprising bonds which are hydrolysable under physiological conditions. More particularly, the hydrogel consists of two interpenetrating polymer networks interconnected to one another through hydrolysable spacers. In addition, the invention relates to a method for the preparation of a hydrogel, wherein macromolecules, e.g. polymers, which contain bonds which are hydrolysable under physiological conditions, are cross-linked in an aqueous solution.</p>	

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MR	Mauritania	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

Title: Hydrolysable hydrogels for controlled release.

The present invention relates to hydrogels which have a good controlled release behaviour, and to processes to prepare such hydrogels.

The fast developments in the field of molecular
5 biology and biotechnology have made it possible to produce a large number of pharmaceutically interesting products in large quantities. For instance, pharmaceutically active peptides and proteins can suitably be used as drugs in the treatment of life-threatening diseases, e.g. cancer, and
10 of several types of viral, bacterial and parasital diseases; in the treatment of e.g. diabetes; in vaccines, e.g. for prophylactic aims, and for anticonception purposes. Especially the specialized biological activities of these types of drugs provide tremendous advantages over
15 other types of pharmaceuticals.

To illustrate the fast developments, it has been reported (see e.g. Soeterboek and Verheggen, Pharm. Weekblad 130 (1995) 670-675) that in the United States of
America, about 275 biotechnological products are in phase
20 IV studies, while more than 500 products are under investigation.

Examples of (recombinant) proteins, which are considered very interesting from a pharmacological point of view, are cytokines, such as interleukines,
25 interferons, tumor necrosis factor (TNF), insulin, proteins for use in vaccines, and growth hormones.

Due to their nature, proteins and proteinaceous products, including peptides, which group of products will be referred to as protein drugs herein-below, cannot be
30 administered orally. These products tend to degrade rapidly in the gastro-intestinal tract, in particular because of the acidic environment and the presence of proteolytic enzymes therein.

Proteins can be incorporated in pharmaceutical delivery systems, e.g. microspheres, by a variety of processes. *In vitro* and *in vivo*, usually a biphasic release profile is observed: an initial burst followed by
5 a more gradual release. The burst is caused by proteinaceous material present at or near the surface of the microspheres and by proteinaceous material present in pores. The gradual release is ascribed to a combination of diffusion of the proteinaceous material through the matrix
10 and degradation of the matrix. Especially for larger proteins diffusion in these matrices is negligible, so that the release depends on the degradation of the polymer. The degradation can be influenced by the (co)polymer composition. A well-known strategy to increase
15 the degradation rate of PLA is co-polymerization with glycolic acid.

Although delivery systems based on biodegradable polymers are interesting, it is very difficult to control the release of the incorporated protein. This hampers the
20 applicability of these systems, especially for proteins with a narrow therapeutic window, such as cytokines and hormones. Furthermore, organic solvents have to be used for the encapsulation of the protein in these polymeric systems. Exposure of proteins to organic solvents
25 generally leads to denaturation, which will affect the biological activity of the protein. Furthermore, the very stringent requirements of registration authorities with respect to possible traces of harmful substances may prohibit the use of such formulations of therapeutic drugs
30 in human patients.

Also hydrogels are frequently used as delivery systems for proteins and peptides. Hydrogels can be obtained by crosslinking a water-soluble polymer yielding a three-dimensional network which can contain large
35 amounts of water. Proteins can be loaded into the gel by adding the protein to the polymer before the crosslinking reaction is carried out or by soaking a preformed hydrogel

days. Dextran hydrogels, wherein the dextrans have a higher degree of substitution, did not show any signs of degradation during 70 days, even at extreme conditions.

The object of the present invention is to provide a
5 slow or controlled release delivery system which does not possess the above-mentioned disadvantages, and especially does not require the use of organic solvents, does not show the undesired and uncontrollable burst effects, and do not possess a poorly controllable release behaviour.
10 The present invention aims to combine the advantages of both types of known delivery systems, viz. a system, (bio)degradable under physiological conditions - either chemically and/or enzymatically -, with controlled protein drug release.

15 The present invention provides safe and easily controllable delivery systems, based on particular biodegradable hydrogels, which increase the applicability of protein drugs for the treatment of various diseases. The risks associated with these drugs, such as bursts in
20 the release profile, and the inconvenience for the patient are reduced, while the therapeutic efficacy of drug treatments using the hydrogels of the present invention is increased.

More in detail, the present invention relates to a
25 biodegradable hydrogel comprising bonds which are hydrolysable under physiological conditions. The hydrogels of the present invention contain hydrolytically labile spacers, which spacers are broken in human or animal bodies. As roughly indicated herein-above, a hydrogel is
30 defined as a water-swollen, three-dimensional network of crosslinked hydrophilic macromolecules. More in detail, the hydrogels of the invention consist of two interpenetrating networks interconnected to one another through hydrolysable spacers. Hydrogels generally contain
35 from 20 to more than 99 wt.% water.

Further, the invention relates to a method for the preparation of a hydrogel, wherein macromolecules, e.g.

polymers, which contain bonds which are hydrolysable under physiological conditions, are crosslinked in an aqueous solution.

In accordance with the present invention, all types
5 of biodegradable hydrogels can be used, provided that hydrolytically labile spacers can be introduced in these structures. When brought into the system of an animal or human body, the hydrogel structure is more or less gradually broken down. The degradation products do not
10 need to be removed after therapy; they can simply be metabolized and/or excreted by the body.

Preferably, the hydrogels are based on water soluble polymers which contain at least a number of side groups having the capability to form linkers to other polymers,
15 e.g. dextran or derivatized dextrans, while starches and starch derivatives, cellulose derivatives such as hydroxyethyl and hydroxypropyl cellulose, polyvinylpyrrolidone, proteins, polyamino acids, polyvinylalcohol, polyacrylates, polymethacrylates,
20 polyethylene glycols that contain a number of monomer units capable of forming side chains, and so on, can also be used, as well as copolymers thereof.

The hydrogels of the invention are suitably based on a polymer crosslinked with methacrylate units. Other
25 crosslinking units are acrylate units, vinyl ethers and vinyl esters, as well as other units known for this purpose by the person skilled in the art.

Generally, the water-swellaable polymers used in the present invention are made hydrolysable by introducing at
30 least one hydrolytically labile unit in the spacers between the main chains of water soluble polymers and the second polymer chain formed by the crosslinkable units as described in the preceding paragraph. It is also possible to use polymer chains comprising hydrolytically labile
35 monomer units in the main chain. However, not within the scope of the present invention are hydrogels which only contain polymer chains that are interconnected head-to-

polymer, which is probably cleared via the kidneys, as well.

Hydrogels of the present invention can suitably be prepared by first synthesizing spacers which contain at least one crosslinkable group and at least one hydrolytically labile group; coupling such spacers to a water-soluble polymer, and crosslinking the polymers obtained, preferably in the presence of the compound to be released.

Preferred spacers within the present invention comprise a hydroxyethyl methacrylate (HEMA) group, coupled to one or more lactide and/or glycolide units, as exemplified in steps a and b of scheme 1. More in detail, HEMA-terminated polylactic acid pre-polymers can be synthesized by solution polymerization of lactide in toluene using HEMA as initiator and aluminium alkoxide as catalyst or by a bulk polymerization of lactide using HEMA as initiator and stannous octoate as catalyst. Dependent on the ratio HEMA/lactic acid pre-polymers which differ in molecular weight of the lactic acid block can be synthesized. HEMA terminated copolymers of glycolic acid and of glycolic acid-co-lactic acid can be synthesized in analogy. The pre-polymers can be characterized by known techniques; e.g. NMR and IR spectroscopy, differential scanning calorimetry (DSC), and gel permeation chromatography (GPC). In order to couple the HEMA terminated polylactic and/or glycolic acid pre-polymers to dextran, the terminal hydroxyl group has to be activated. Preferably, the binding of HEMA to dextran is effected by carbonyl-di-imidazole (CDI) as coupling agent. However, also other activation methods can be used. For example, reaction of the hydroxyl function of the HEMA lactic acid pre-polymer with succinic anhydride, followed by activation of the formed carboxylic group using established methods (e.g. dicyclohexylcarbodiimide (DCC) activation). The latter method yields dextran derivatives in which only hydrolytically instable ester bonds are

The hydrogels of the present invention can be prepared in such a way that dissolution times from less than 1 day upto about 3 months and longer can be obtained. This can for instance be effected by varying the initial
5 water content in the aqueous polymer solution to be crosslinked and the DS. Gels with a high initial water content, such as water contents higher than 85 wt.% predominantly contain intramolecular crosslinks, while lower initial water contents give more intermolecular
10 crosslinking. Gels with less intermolecular crosslinks dissolve faster at the same DS.

Drugs can be loaded into hydrogels either by equilibration in a drug-containing solution (see e.g. Kim et al. in Pharm. Res. 9(3) (1992) 283-290) or by
15 incorporation of the drug during the preparation of hydrogel (see e.g. Heller et al. in Biomaterials 4 (1983) 262-266).

Loading by equilibration, however, normally leads to a rather low drug content in the delivery system. This is
20 especially the case, when the drug is a macromolecular compound. Unless the pore size of the hydrogel is rather large, the macromolecules will only adhere to the outer surface, which may lead to a burst release.

Therefore, preferably, the drug is loaded during
25 polymerization or crosslinking.

Since microsphere suspensions are easy to prepare and are easily used for injection, the hydrogels generally will be applied as microspheres of varying sizes. Microspheres can be prepared by dissolving
30 HEMA-derivatized dextran in water after which this solution is added to an oil phase (e.g. silicone oil) yielding a water-in-oil emulsion. After addition of a suitable initiator system, the methacrylate groups polymerize, yielding stable microspheres.

35 The drugs are released from the biodegradable hydrogels of the present invention during hydrolysis of the hydrogel, although at least to some extent diffusion

- 11 -

of proteins from the hydrogel takes place. In fact, the hydrolysis behaviour of the hydrogel and the time during which compounds present in the hydrogel system are released can be adjusted to one another so that the release can take place at any level between first order (no degradation of the hydrogel) and zero order release (fully degradation controlled) (see in this respect Example 6, herein-below). This provides evident advantage over hydrogel systems that are not hydrolysable at physiological conditions, but which are rather stable, such as the known dextran-GMA hydrogel system, or over systems wherein the polymers in the hydrogel are elongated in one dimension only.

Protein drugs are released from the rather stable hydrogels following first order kinetics - protein release proportional to the square root of time - which is common for monolithic delivery systems. The hydrogels of the present invention, however, show a more zero order release behaviour - protein release proportional to time. When the hydrogel degrades during the release process, the diffusion coefficient of the protein drug, present in the hydrogel, increases. This leads to a more constant release in time.

The hydrogel system of the present invention offers - as said - the possibility to tailor the release profiles of encapsulated protein drugs. More in detail, the degradation rate of the hydrogel can be adjusted by varying the water content of the hydrogel, the degree of substitution, the number and length of hydrolysable groups in the spacers, and the choice of hydrolysable spacers.

It has been found that spacers based on glycolic acid have a higher hydrolytical sensitivity than spacers based on lactic acid. If glycolic acid based spacers are present an accelerated degradation rate of the hydrogel is observed as compared with lactic acid based spacers.

A major disadvantage of the intravenous route is that for obtaining sufficiently high levels of IL-2 at the site of tumor growth, such high doses of IL-2 have to be administered intravenously, that it becomes severely
5 toxic. In contrast, the intra- or peri-tumoral approach, as developed by Den Otter et al., has proven to be very successful and virtually non-toxic in various transplanted and spontaneous tumors.

A serious problem for application of this form of
10 therapy in human cancer patients, however, is that IL-2 has to be injected intra- or peri-tumorally 5 to 10 times within 1 to 2 weeks. For many types of cancer this is not-acceptable burden for the patient, like in cases of lung carcinoma, bladder cancer, and gastric cancer. In first
15 attempts to translate the very effective local, low-dose IL-2 treatment to the human cancer clinic, these logistic problems of IL-2 delivery were already run into. The slow-release delivery system of the present invention makes the use of local IL-2 immunotherapies possible.

20 For the *in vivo* application hydrogel suspensions (microspheres) will normally contain up to 10^5 I.U. of IL-2 in 0.5 ml, which are released over a period of 5 days (i.e. 2×10^4 I.U. of IL-2 released per day). The amount of protein released can be determined with sensitive
25 quantitative detection methods (HPLC, ELISA assays). To investigate whether the released IL-2 is still biologically active and to what extent (i.e. what is the effect of these chemical procedures on the specific activity of IL-2), proliferation assays using the IL-2
30 dependent CTLL cell line can be performed.

The present invention will now be explained in more detail, while referring to the following, non-limiting examples.

- 15 -

(DMSO; 90 ml). These reaction mixtures were stirred for 4 days at room temperature after which the reaction was terminated by the addition of about 2 ml of concentrated HCl. The reaction mixture was dialyzed against water for 3 days at 4°C. Dex-HEMA was isolated by lyophilization yielding a white fluffy material (yield >90%). The degree of HEMA substitution was determined by NMR spectroscopy, and amounted 4, 9, and 13, respectively.

Example 2: Synthesis of dex-SA-HEMA

10 Dextran derivatized with the hemi-ester of succinic acid (SA) and HEMA (dex-SA-HEMA) was synthesized as follows.

SA (2.00 g, 20 mmol), HEMA (2,6 g, 20 mmol), triethylamine (TEA; 0.28 ml, 2 mmol) and hydrochinon
15 (inhibitor, ± 10 mg) were dissolved in about 30 ml anhydrous THF. The reaction mixture was stirred for 2 days at 45°C, after which the solvent was evaporated. A yellow liquid was obtained (yield 4.88 g). The structure of HEMA-SA was confirmed by NMR and IR spectroscopy.

20 HEMA-SA (0.99 g (94% pure), 4 mmol) and dicyclohexylcarbodiimide (DCC; 0.83 g, 4 mmol) were dissolved in about 20 ml anhydrous DMSO. After 15 minutes a precipitate was formed (dicyclohexylureum; DCU) and this mixture was added to a solution of dextran (2.57 g,
25 16 mmol glucose units) and TEA (0.56 ml, 4 mmol) in anhydrous DMSO (20 ml). The resulting mixture was stirred for 3 days at room temperature, after which 3 drops of concentrated HCl were added to terminate the reaction. Next, the reaction mixture was filtered to remove DCU and
30 dialyzed for 3 days at 4°C. After lyophilization, a white fluffy product was obtained (yield 2.78 g). The degree of substitution was established by NMR spectroscopy and amounted to 3.

The hydrogels of the present invention can be prepared in such a way that dissolution times from less than 1 day upto about 3 months and longer can be obtained. This can for instance be effected by varying the initial
5 water content in the aqueous polymer solution to be crosslinked and the DS. Gels with a high initial water content, such as water contents higher than 85 wt.% predominantly contain intramolecular crosslinks, while lower initial water contents give more intermolecular
10 crosslinking. Gels with less intermolecular crosslinks dissolve faster at the same DS.

Drugs can be loaded into hydrogels either by equilibration in a drug-containing solution (see e.g. Kim et al. in Pharm. Res. 9(3) (1992) 283-290) or by
15 incorporation of the drug during the preparation of hydrogel (see e.g. Heller et al. in Biomaterials 4 (1983) 262-266).

Loading by equilibration, however, normally leads to a rather low drug content in the delivery system. This is
20 especially the case, when the drug is a macromolecular compound. Unless the pore size of the hydrogel is rather large, the macromolecules will only adhere to the outer surface, which may lead to a burst release.

Therefore, preferably, the drug is loaded during
25 polymerization or crosslinking.

Since microsphere suspensions are easy to prepare and are easily used for injection, the hydrogels generally will be applied as microspheres of varying sizes.

Microspheres can be prepared by dissolving
30 HEMA-derivatized dextran in water after which this solution is added to an oil phase (e.g. silicone oil) yielding a water-in-oil emulsion. After addition of a suitable initiator system, the methacrylate groups polymerize, yielding stable microspheres.

35 The drugs are released from the biodegradable hydrogels of the present invention during hydrolysis of the hydrogel, although at least to some extent diffusion

- 11 -

of proteins from the hydrogel takes place. In fact, the hydrolysis behaviour of the hydrogel and the time during which compounds present in the hydrogel system are released can be adjusted to one another so that the release can take place at any level between first order (no degradation of the hydrogel) and zero order release (fully degradation controlled) (see in this respect Example 6, herein-below). This provides evident advantage over hydrogel systems that are not hydrolysable at physiological conditions, but which are rather stable, such as the known dextran-GMA hydrogel system, or over systems wherein the polymers in the hydrogel are elongated in one dimension only.

Protein drugs are released from the rather stable hydrogels following first order kinetics - protein release proportional to the square root of time - which is common for monolithic delivery systems. The hydrogels of the present invention, however, show a more zero order release behaviour - protein release proportional to time. When the hydrogel degrades during the release process, the diffusion coefficient of the protein drug, present in the hydrogel, increases. This leads to a more constant release in time.

The hydrogel system of the present invention offers - as said - the possibility to tailor the release profiles of encapsulated protein drugs. More in detail, the degradation rate of the hydrogel can be adjusted by varying the water content of the hydrogel, the degree of substitution; the number and length of hydrolysable groups in the spacers, and the choice of hydrolysable spacers.

It has been found that spacers based on glycolic acid have a higher hydrolytical sensitivity than spacers based on lactic acid. If glycolic acid based spacers are present an accelerated degradation rate of the hydrogel is observed as compared with lactic acid based spacers.

The effect of the water content of the hydrogel and the degree of substitution of the hydrogel polymers is elaborated in the examples following below.

Further, the rate of release depends on the size of
5 the hydrogel particles. This size can be adjusted by varying the stirring speed, viscosity of the external phase etc. during the preparation of microspheres.

The rate of release does not depend on the length of the water soluble polymers, at least not to a high extent.
10 This is contrary to hydrogel systems wherein the hydrolysable groups are present in the main chains of the polymer only (one dimensionally elongated polymers).

As indicated herein-above, the releasable compound can be a protein drug. However, it is also possible to
15 encapsulate pharmacon containing nanoparticles, e.g. liposomes, iscoms, polylactic acid particles, polycaprolacton particles and gene delivery systems known to the person skilled in the art. The encapsulation of these nanoparticles has the advantage of preventing the
20 occurrence of a too fast release of the encapsulated compound, or, said in other words, burst-effects can be avoided in a more secure way.

An example of a loaded hydrogel system within the present invention is a hydrogel containing the cytokine
25 interleukin-2 (IL-2). IL-2 is a protein drug which can e.g. be used in the treatment of particular types of cancer.

For IL-2 to be therapeutically effective in cancer treatment, prolonged presence of IL-2 at the site of tumor
30 growth is required. This can be achieved either by administering high doses of IL-2 intravenously through frequent bolus injections (see e.g. Rosenberg et al. JAMA
271, (1994) 907-913), by prolonged continuous infusion (see e.g. West et al., N. Engl. J. Med. 316, (1987),
35 898-905, or by frequently administering low doses of IL-2 intra- or peri-tumorally (see e.g. Den Otter et al., Anticancer Res. 13, (1993), 2453-2455).

A major disadvantage of the intravenous route is that for obtaining sufficiently high levels of IL-2 at the site of tumor growth, such high doses of IL-2 have to be administered intravenously, that it becomes severely
5 toxic. In contrast, the intra- or peri-tumoral approach, as developed by Den Otter et al., has proven to be very successful and virtually non-toxic in various transplanted and spontaneous tumors.

A serious problem for application of this form of
10 therapy in human cancer patients, however, is that IL-2 has to be injected intra- or peri-tumorally 5 to 10 times within 1 to 2 weeks. For many types of cancer this is not-acceptable burden for the patient, like in cases of lung carcinoma, bladder cancer, and gastric cancer. In first
15 attempts to translate the very effective local, low-dose IL-2 treatment to the human cancer clinic, these logistic problems of IL-2 delivery were already run into. The slow-release delivery system of the present invention makes the use of local IL-2 immunotherapies possible.

20 For the *in vivo* application hydrogel suspensions (microspheres) will normally contain up to 10^5 I.U. of IL-2 in 0.5 ml, which are released over a period of 5 days (i.e. 2×10^4 I.U. of IL-2 released per day). The amount of protein released can be determined with sensitive
25 quantitative detection methods (HPLC, ELISA assays). To investigate whether the released IL-2 is still biologically active and to what extent (i.e. what is the effect of these chemical procedures on the specific activity of IL-2), proliferation assays using the IL-2
30 dependent CTLL cell line can be performed.

The present invention will now be explained in more detail, while referring to the following, non-limiting examples.

Examples

To obtain a dextran hydrogel, first a polymerizable methacrylate group was introduced in dextran. For all reactions described below, dextran from Fluka (T40, $M_n = 15.000$, $M_w = 32.500$ g/mol) was used. Four different dextran derivatives were synthesized (Examples 1-4) in which the methacrylate ester was coupled via a spacer to dextran. The spacer contains different hydrolyzable bonds (carbonate and/or carboxylic ester). The degradation behaviour of gels prepared from these derivatives was compared with dextran gels derived from glycidylmethacrylate (dex-GMA). In this reference compound, the methacrylate ester is directly coupled to a hydroxyl group of dextran. This reference gel degrades extremely slowly.

Example 1: Synthesis of dex-HEMA

Dextran derivatized with hydroxyethyl methacrylate (dex-HEMA) was synthesized by coupling carbonyldiimidazole (CDI) activated HEMA (HEMA-CI) to dextran.

CDI (1.62 g; 10 mmol) was dissolved in about 10 ml anhydrous tetrahydrofuran (THF). This solution was added to a solution of HEMA (1.30 g; 10 mmol) in 5 ml anhydrous THF. The reaction mixture was stirred for 16 hours at room temperature. After evaporation of the solvent a slightly yellow liquid was obtained (yield 2.93 g). The crude product was dissolved in ethylacetate, extracted with water to remove imidazole and unreacted HEMA and dried on anhydrous $MgSO_4$. After filtration, the solvent was evaporated and almost pure hydroxyethyl methacrylate activated with CDI (HEMA-CI) was obtained. The structure of this product was confirmed by NMR and IR spectroscopy.

Varying amounts of HEMA-CI (0.73, 1.49, or 2.19 g; 96% pure) were added to a solution of dextran (10 g, 62 mmole glucose units) and *N,N*-dimethylaminopyridine (DMAP; 2 g, 16.4 mmol) in anhydrous dimethylsulfoxide

- 15 -

(DMSO; 90 ml). These reaction mixtures were stirred for 4 days at room temperature after which the reaction was terminated by the addition of about 2 ml of concentrated HCl. The reaction mixture was dialyzed against water for 3 days at 4°C. Dex-HEMA was isolated by lyophilization yielding a white fluffy material (yield >90%). The degree of HEMA substitution was determined by NMR spectroscopy, and amounted 4, 9, and 13, respectively.

Example 2: Synthesis of dex-SA-HEMA

10 Dextran derivatized with the hemi-ester of succinic acid (SA) and HEMA (dex-SA-HEMA) was synthesized as follows.

SA (2.00 g, 20 mmol), HEMA (2,6 g, 20 mmol), triethylamine (TEA; 0.28 ml, 2 mmol) and hydrochinon (inhibitor, ± 10 mg) were dissolved in about 30 ml anhydrous THF. The reaction mixture was stirred for 2 days at 45°C, after which the solvent was evaporated. A yellow liquid was obtained (yield 4.88 g). The structure of HEMA-SA was confirmed by NMR and IR spectroscopy.

20 HEMA-SA (0.99 g (94% pure), 4 mmol) and dicyclohexylcarbodiimide (DCC; 0.83 g, 4 mmol) were dissolved in about 20 ml anhydrous DMSO. After 15 minutes a precipitate was formed (dicyclohexylureum; DCU) and this mixture was added to a solution of dextran (2.57 g, 25 16 mmol glucose units) and TEA (0.56 ml, 4 mmol) in anhydrous DMSO (20 ml). The resulting mixture was stirred for 3 days at room temperature, after which 3 drops of concentrated HCl were added to terminate the reaction. Next, the reaction mixture was filtered to remove DCU and dialyzed for 3 days at 4°C. After lyophilization, a white fluffy product was obtained (yield 2.78 g). The degree of substitution was established by NMR spectroscopy and amounted to 3.

Example 3: Synthesis of dex-lactate-HEMA

Dextran derivatized with HEMA-oligolactide was synthesized as follows as illustrated in scheme 1. Three steps can be distinguished.

- 5 a. coupling of lactate to HEMA yielding HEMA-lactate;
- b. activation of HEMA-lactate using CDI yielding HEMA-lactate-CI
- c. coupling of HEMA-lactate-CI to dextran.

A mixture of L-lactide (4.32 g; 30 mmol) and HEMA
10 (3.90 g; 30 mmol) was heated to 110°C. Thereafter, a catalytic amount of stannous octoate (SnOct_2 ; 121.5 mg, 0.3 mmol) dissolved in about 0.5 ml toluene was added. The resulting mixture was stirred for 1 hour. After cooling
15 down to room temperature, the mixture was dissolved in THF (20 ml). This solution was dropped in water (180 ml) and the formed precipitate was isolated by centrifugation. The pellet was taken up in ethyl acetate (40 ml),
centrifugated to remove solid material, dried (MgSO_4) and filtered. The solvent was evaporated yielding a viscous
20 oil (3.74 g, 45%). The product (HEMA-lactate) was characterized by NMR and IR spectroscopy.

HEMA-lactate (3.74 g, 10.8 mmol) was added to a solution of CDI (1.76 g, 10.8 mmol) in THF and stirred for
16 hours at room temperature. The solvent was evaporated
25 under reduced pressure yielding a viscous oil. The product containing HEMA-lactate-CI and imidazole as major compounds (NMR analysis) was used without further purification.

To a solution of dextran (10 g, 62 mmol glucose
30 units) and DMAP (2.0 g, 10.6 mmol) a varying amount of HEMA-lactate-CI was added (1.61, 3.23 or 4.84 g respectively, 80% pure). These mixtures were stirred for
4 days at room temperature after which the reaction was terminated by the addition of about 2 ml of concentrated
35 HCl. The solutions were dialyzed against water for 2 days.

- 17 -

After lyophilization, white fluffy products were obtained (yield around 85%). The degree of substitution (as determined by NMR spectroscopy) amounted to 3, 6 and 10 for the three products, respectively.

- 5 Using similar procedures, the length of the lactate spacer can be varied by changing the molar ratio of HEMA and lactide in the first reaction.

Example 4: Synthesis of dex-glycolide-HEMA

- 10 Dex-glycolide-HEMA was synthesized according to the same procedure as described in Example 3 replacing lactide by glycolide.

Reference Example 1: Dex-GMA

Dex-GMA was synthesized as described by Van Dijk-Wolthuis et al., *Macromolecules* **28**, (1995), 6317-6322. An
15 reinvestigation of the obtained dextran derivative revealed that the methacrylic ester group is directly coupled to one of the hydroxylic group of dextran, meaning that the glyceryl spacer is not present.

Example 5: Preparation of dextran hydrogels

- 20 Hydrogels were obtained by a free radical polymerization of aqueous solutions of methacrylated dextran (prepared according to Examples 1-4 and Ref. Example 1). Methacrylated dextran (100 mg) was dissolved in 760 µl PBS buffer (10 mM phosphate, 0.9%
25 NaCl, 0.02% NaN₃, pH 7.2). To this solution 90 µl of potassium peroxydisulfate (KPS; 50 mg/ml) in the same buffer was added per gram solution and mixed well. Subsequently, N,N,N',N'-tetramethylethylenediamine (TEMED; 50 µl; 20% (v/v) in water, pH adjusted to 7) was added and
30 the resulting solution was quickly transferred into an Eppendorf tube and polymerized for 1 hour at room temperature yielding a hydrogel material with an initial water content of about 90% (w/w) after polymerization.

- 18 -

The gels were removed from the tubes, accurately weighed and incubated in PBS at 37°C. Periodically, the weight of the gels was determined and used to calculate the degree of swelling ($= W_t/W_0$, in which W_t is the weight of the gel at time t and W_0 is the initial weight of the gel). The hydrogel degradation (dissolution) time is defined as the time at which the swelling ratio = 0 (or $W_t = 0$).

Figure 1 shows the swelling behaviour of three different dextran hydrogels (initial water content 90%). The dex-GMA (DS = 4) reached an equilibrium swelling within 3 days; thereafter the weight of the gels remained constant indicating that no significant hydrolysis of methacrylate esters occurred. Dex-HEMA and dex-lactate-HEMA showed a progressive swelling in time until these gels dissolved completely. This demonstrates that in these hydrogel systems hydrolysis of carbonate esters (dex-(lactate)HEMA) and/or lactate esters (dex-lactateHEMA) occurred.

Figure 2 shows the swelling behaviour of dex-lactateHEMA hydrogels (initial water content 92%) and varying degree of substitution. As can be seen an increasing DS resulted in an increasing dissolution time.

Figure 3 shows the swelling behaviour of dex-lactateHEMA hydrogels with a fixed DS (6) and varying initial water content. It appears that the dissolution time increases with an increasing initial water content.

Figure 4 shows the swelling behaviour of dex-SAHEMA hydrogel (DS 3) and a varying initial water content.

- 19 -

The next tables give an overview of the dissolution times of different dextran hydrogels

dissolution time (days) of dex-lactate-HEMA gels				
	initial water content	DS 10	DS 6	DS 2.5
5	90%	8-13	4	1-2
	80%	16	7-18	3-9
	70%	22	10-19	6-10

dissolution time (days) of dex-HEMA gels				
	initial water content	DS 8	DS 17	DS 20
10	92%	25	42	55
	80%	53	100	ND
	67%	70	>100	ND

dissolution time (days) of dex-HEMA-SA gels				
	initial water content	DS 3		
15	80%	15		
	74%	23-28		
	60%	44		

The dissolution time of dextran hydrogels (initial water content 92%) obtained by polymerization of dextran derivatized with GMA (DS 4) had a dissolution time of about 100 days (pH 7.2, 37°C). Gels obtained by polymerization of dextran derivatized with GMA (initial water content 80%, DS 11) did not show any signs of degradation (increased swelling) during 70 days, even at extreme conditions (37°C, pH 12 and pH 1).

Example 6: Protein release from degrading dextran hydrogels

The release from non-degrading dex-GMA hydrogels has been studied extensively. It appeared that when the protein diameter was smaller than the hydrogel mesh size, the release of the protein could be effectively described by the free volume theory. In this case the cumulative amount of protein released was proportional to the square

- 20 -

root of time (W.E. Hennink, Controlled release of proteins from dextran hydrogels, Journal of Controlled Release 39, (1996), 47-55).

Figure 5 shows the release of a model protein (IgG) from degrading dextran hydrogels (dex-lactate-HEMA, DS 2.5). The release of IgG from these degrading gels is zero order (cumulative release proportional to time). This is in contrast with the release of proteins from non-degrading dextran hydrogels, where a first order release has been observed.

1/5

Figure 1. Influence of spacer on the swelling ratio of dextran hydrogels




Figure 2. Influence of the DS on the swelling ratio of dex-lactate-HEMA hydrogels




Figure 3. Influence of the initial water content of dex-lactateHEMA hydrogels on the swelling ratio






Figure 4. Swelling behaviour of dex-SA-HEMA hydrogels





INTERNATIONAL SEARCH REPORT

Intern: Application No

PCT/NL 97/00374

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 024 073 A (SHIMIZU ET AL) 17 May 1977 see the whole document see column 2; table 1 ---	1-3,5,6
A	W.E. HENNINK ET AL.: "CONTROLLED RELEASE OF PROTEINS FROM DEXTRAN HYDROGELS" JOURNAL OF CONTROLLED RELEASE, vol. 39, no. 1, March 1996, AMSTERDAM (NL), pages 47-55, XP000583520 cited in the application see the whole document -----	

- (3) Park, K.; Shalaby, W. S. W.; Park, H. *Biodegradable hydrogels for drug delivery*; Technomic Publishing Co.: Lancaster, PA, 1993.
- (4) Yoshida, R.; Sakai, K.; Okano, T.; Sakurai, Y. *Adv. Drug Delivery Rev.* **1993**, *11*, 85-108.
- (5) Cheng, J.; Jo, S.; Park, K. *Carbohydr. Polym.* **1995**, *28*, 69-76.
- (6) Dowes, S.; Patel, M.; Silvo, L. D.; Swai, H.; Davy, K.; Braden, M. *Biomaterials* **1995**, *16*, 1417-1421.
- (7) Peppas, N. A.; Scott, J. E. *J. Controlled Release* **1992**, *18*, 95-100.
- (8) Merrill, E. W.; Dennison, K. A.; Sung, C. *Biomaterials* **1993**, *14*, 1117-1126.
- (9) Sawhney, A. S.; Pathak, C. P.; Hubbell, J. A. *Macromolecules* **1993**, *26*, 581-587.
- (10) West, J. L.; Hubbell, J. A. *React. Polym.* **1995**, *25*, 139-147.
- (11) Ulbrich, K.; Šubr, V.; Seymour, L. W.; Duncan, R. J. *Controlled Release* **1993**, *24*, 181-190.
- (12) Ulbrich, K.; Šubr, V.; Podperová, P.; Burešová, M. *J. Controlled Release* **1995**, *34*, 155-165.
- (13) Hennink, W. E.; Talsma, H.; Borchert, J. C. H.; De Smedt, S. C.; Demeester, J. J. *Controlled Release* **1996**, *39*, 47-55.
- (14) Franssen, O.; Vos, O.; Hennink, W. E. *J. Controlled Release* **1997**, *44*, 237-245.
- (15) Van Dijk-Wolthuis, W. N. E.; Franssen, O.; Talsma, H.; van Steenberg, M. J.; Kettenes-van den Bosch, J. J.; Hennink, W. E. *Macromolecules* **1995**, *28*, 6317-6322.
- (16) Van Dijk-Wolthuis, W. N. E.; van der Kerk-van Hoof, A.; Kettenes-van den Bosch, J. J.; Hennink, W. E. *Macromolecules* **1997**, *30*, 3411-3413.
- (17) Van Dijk-Wolthuis, W. N. E.; Tsang, S. K. Y.; Kettenes-van den Bosch, J. J.; Hennink, W. E. *Polymer*, accepted for publication.
- (18) Porsch, B.; Sundelöf, L.-O. *J. Chromatogr. A* **1994**, *699*, 21-30.
- (19) Flory, P. J.; Rehner, R. *J. Chem. Phys.* **1943**, *11*, 521-526.
- (20) Peppas, N. A.; Merrill, E. W. *J. Polym. Sci., Part A: Polym. Chem.* **1976**, *14*, 441-457.
- (21) Errington, N.; Harding, S. E.; Illum, L.; Schacht, E. H. *Carbohydr. Polym.* **1992**, *18*, 289-294.
- (22) Gekko, H. In *ACS Symposium Series* Vol. 150; Brant, D. A., Ed.; American Chemical Society: Washington, DC, 1981; pp 415-438.
- (23) Bradford, M. *Anal. Biochem.* **1976**, *72*, 248-254.
- (24) Flory, P. J. In *Principles of polymer chemistry*; Cornell University Press: Ithaca, NY, 1953; p 577.
- (25) Van Dijk-Wolthuis, W. N. E.; van Steenberg, M. J.; Underberg, W. J. M.; Hennink, W. E. *J. Pharm. Sci.* **1997**, *86*, 413-417.
- (26) Kawabe, H.; Yanagita, M. *Bull. Chem. Soc. Jpn.* **1969**, *42*, 3109-3115.
- (27) Bevington, J. C.; Eaves, D. E.; Vale, R. L. *J. Polym. Sci.* **1958**, *32*, 317-322.
- (28) Pitt, C. G.; Gu, Z. W. *J. Controlled Release* **1987**, *4*, 283-292.
- (29) De Smedt, S. C.; Lauwers, A.; Demeester, J.; van Steenberg, M. J.; Hennink, W. E.; Roefs, S. P. F. M. *Macromolecules* **1995**, *28*, 5082-5088.
- (30) Ritger, P. L.; Peppas, N. A. *J. Controlled Release* **1987**, *5*, 23-36.
- (31) Ritger, P. L.; Peppas, N. A. *J. Controlled Release* **1987**, *5*, 37-42.

MA9704018